The latest news, releases and announcements making a difference
SUV SPECT® QUANTITATIVE RECONSTRUCTION FROM HERMES MEDICAL SOLUTIONS EVALUATED BEST-IN-CLASS FOR SIRT WITH 166HO MICROSPHERES
Greenville, NC, November 8, 2021
Hermes Medical Solutions (HMS), leader in molecular imaging software development, has been recognized by Quirem Medical, a Terumo company, to provide the best commercially available and fully approved software for accurate quantitative reconstruction of 166Ho SPECT/CT scans for use with their exciting SIRT products QuiremScout® and QuiremSpheres®.
HERMES MEDICAL SOLUTIONS & ISOTOPIA MOLECULAR IMAGING ANNOUNCE A NEW COLLABORATION FOCUSED ON DOSIMETRY
Greenville, NC, September 7, 2021
Hermes Medical Solutions (HMS), global market leader in molecular imaging and dosimetry software solutions, enters a close collaboration with Isotopia to raise awareness and co-promote benefits of dosimetry, radiopharmaceutical therapy (RPT) and personalized medicine.
HERMES MEDICAL SOLUTIONS RECEIVES CE MARK & HEALTH CANADA CLEARANCE FOR SINGLE TIME POINT VOXEL DOSIMETRY™
SNMMI 2021 Virtual Annual Meeting, June 14, 2021
Hermes Medical Solutions (HMS), global market leader in molecular imaging and dosimetry software solutions, releases Voxel Dosimetry™ 1.1 in Europe and Canada. This latest version includes groundbreaking single time point dosimetry calculations. HMS strives to deliver the most accurate dosimetry application for Theranostics and personalized radionuclide therapies.
HERMES MEDICAL SOLUTIONS SIGNS A DISTRIBUTION AGREEMENT WITH TTG IMAGING SOLUTIONS TO ACCELERATE ITS EXPANSION IN THE U.S.
Greenville, NC, June 4, 2021
Hermes Medical Solutions (HMS), leader in molecular imaging software development, enters a distribution agreement with TTG Imaging Solutions (TTG). HMS and TTG are leveraging shared synergies, to improve molecular imaging patients’ pathways in the United States.
HERMES MEDICAL SOLUTIONS PARTNERS WITH RADIOLOGY ONCOLOGY SYSTEMS TO INCREASE ACCESS TO MOLECULAR IMAGING’S ADVANCEMENTS WITHIN CANCER CARE IN THE US
Greenville, NC, May 21, 2021
Hermes Medical Solutions and Radiology Oncology Systems join forces to deliver cost-efficient and innovative solutions to Medical Imaging and Radiotherapy Departments, throughout the United States.
Stockholm – January 17, 2020
Hermes Medical Solutions receives 510(k) FDA clearance for Affinity Stockholm – January 17, 2020 Hermes Medical Solutions has received 510(k) FDA clearance for its Affinity TM product. The product has previously been CE-marked and Health Canada (MDD). Affinity TM is a complete molecular imaging and nuclear medicine viewing and analysis tool based on the latest …
Stockholm – October 18, 2019
Hermes Medical Solutions has received 510(k) FDA clearance for its Voxel Dosimetry TM product. The product has previously been CE-marked. Voxel Dosimetry TM provides estimates (deterministic) of absorbed radiation dose at voxel level as a result of administrating one of the supported radionuclides and providing a 3-dimensional dose map…
Stockholm – October 8, 2019
Hermes Medical Solutions launches Affinity Viewer at EANM 2019 Stockholm – October 8, 2019 The Affinity Viewer differs significantly from all other viewers on the market. We have employed expert developers from the gaming industry to revolutionize the performance and usability of the Affinity Viewer to create a completely new experience for clinical software …
Stockholm – June 15, 2019
Hermes Medical Solutions brings speed and accuracy to Nuclear Medicine imaging at SNMMI Stockholm – June 15, 2019 A complicated workflow is one of the biggest challenges in nuclear medicine processing. At this year’s SNMMI conference, Hermes Medical solutions will show several software applications that will vastly improve the workflow…
Release of Hybrid Recon™ 3.0 with Full Collimator modelling for high energy isotopes Y90, I131, I123 and Ho166
Stockholm – December 14, 2018
Hermes Medical Solutions Releases Hybrid Recon™ 3.0, including Full Collimator modelling for high energy isotopes Y90, I131, I123 and Ho166.
Hybrid Recon™ provides absolute quantification at the point of clinical decision making for Theranostics and Personalized Dosimetry workflows such as SIRT…
Stockholm – October 26, 2018
Hermes Medical Solutions releases Hybrid3D™ SIRT, the only complete and consistent SIRT workflow: Dose Planning with Tc-99mMAA using FDA approved methods of Resin and Glass Microspheres and Dose Verification with Y90 Microspheres. An intuitive end-to-end workflow takes the decision maker through both planning and verification. Hybrid3D™ SIRT continues the Hermes Medical Solutions standard of supporting vendor neutral clinical workflows…
Stockholm – November 25, 2017
Hermes Medical Solutions announces the release of Hybrid 3D™, expanding the extensive clinical capabilities within the Hermes Enterprise Molecular Imaging Platform. Hybrid 3D™ is the first-to-market solution for absolute quantification for multi modality fusion and molecular imaging. Hybrid 3D™ empowers clinical decision makers with the ability to view, fuse and quantify molecular imaging with other rich image data from supporting imaging systems. This unique solution continues to enrich Hermes end-to-end clinical workflow for molecular imaging…